SLC4A4 moulds the inflammatory tumor microenvironment and predicts therapeutic expectations in colorectal cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Solute Carrier Family 4 Member 4 (SLC4A4) promotes an inflammatory tumor microenvironment in colorectal cancer (CRC), influencing immune cell infiltration and predicting therapeutic response. A novel RiskScore aids in assessing CRC prognosis and treatment expectancy.
Area Of Science
- Oncology
- Immunology
- Genomics
Background
- Colorectal cancer (CRC) presents a significant therapeutic challenge, especially in advanced stages, due to limited prognostic markers and treatment targets.
- Solute Carrier Family 4 Member 4 (SLC4A4) is a potential therapeutic target in CRC, but its role in the tumor microenvironment requires further elucidation.
Purpose Of The Study
- To comprehensively analyze the association between SLC4A4 expression and immunological features in CRC.
- To investigate the impact of SLC4A4 on immune cell infiltration and the tumor microenvironment in colorectal cancer.
- To explore the potential of SLC4A4 as a predictive biomarker for immunotherapy response in CRC.
Main Methods
- Utilized RNA sequencing and clinical data from The Cancer Genome Atlas (TCGA) for Colon Adenocarcinoma (COAD) and Rectal Adenocarcinoma (READ).
- Assessed correlations between SLC4A4 expression, immune checkpoint genes (PD-L1, CTLA4), and immune cell infiltration using Spearman correlation.
- Constructed a prognostic assessment system (RiskScore) and a nomogram based on SLC4A4-related differentially expressed genes (DEGs) and clinical factors.
Main Results
- SLC4A4 expression positively correlated with immune checkpoints and promoted infiltration of 27 immune cells, including CD8 T cells, NK cells, and macrophages, fostering an inflammatory tumor microenvironment.
- SLC4A4 expression levels predicted differential responses to various therapies, including immunotherapy (Nivolumab, Ipilimumab) and targeted agents.
- The developed RiskScore demonstrated excellent predictive power and robustness for CRC prognosis, showing a negative correlation with SLC4A4 expression and CRC survival.
- A nomogram incorporating Age, M stage, Stage, and RiskScore showed potential clinical utility for predicting CRC survival.
Conclusions
- Upregulation of SLC4A4 expression contributes to an inflammatory tumor microenvironment in CRC.
- The developed RiskScore effectively predicts therapeutic expectancy and patient prognosis in colorectal cancer.
- SLC4A4 represents a promising and potentially valuable therapeutic target for colorectal cancer treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
